Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

<p>Molecular landscape of HGSOC. <sup>1</sup>Mutation in non-<i>BRCA1</i>/<i>2</i> HRR genes: 3 <i>BRIP1</i>, 2 <i>CHEK2</i>, 1 <i>RAD51C</i>, 1 <i>PALB2</i>, 1 concurrent <i>BAP1</i> and <i>N...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Robert L. Hollis (15034814) (author)
Andere auteurs:	Alison M. Meynert (14956260) (author), Caroline O. Michie (15043392) (author), Tzyvia Rye (4733277) (author), Michael Churchman (15034811) (author), Amelia Hallas-Potts (15043395) (author), Ian Croy (15034823) (author), W. Glenn McCluggage (8775452) (author), Alistair R.W. Williams (15043398) (author), Clare Bartos (15034820) (author), Yasushi Iida (4097272) (author), Aikou Okamoto (14957624) (author), Brian Dougherty (108958) (author), J. Carl Barrett (11900099) (author), Ruth March (73809) (author), Athena Matakidou (15034847) (author), Patricia Roxburgh (14961464) (author), Colin A. Semple (15034853) (author), D. Paul Harkin (14873531) (author), Richard Kennedy (248483) (author), C. Simon Herrington (15034817) (author), Charlie Gourley (15034850) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Biology Tumor Biology Therapeutic Research and Development Clinical Research and Trials Gynecological Cancers Ovarian cancer Oncogenes & Tumor Suppressors BRCA family Precision Medicine Translational Research Tumor Microenvironment Immune cells and the microenvironment
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
door: Robert L. Hollis (15034814)
Gepubliceerd in: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
door: Robert L. Hollis (15034814)
Gepubliceerd in: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
door: Robert L. Hollis (15034814)
Gepubliceerd in: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
door: Robert L. Hollis (15034814)
Gepubliceerd in: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
door: Robert L. Hollis (15034814)
Gepubliceerd in: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
door: Jennifer L. Cotton (17315204)
Gepubliceerd in: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
door: Sanna Pikkusaari (15055802)
Gepubliceerd in: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
door: Sanna Pikkusaari (15055802)
Gepubliceerd in: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
door: Kankan Cao (16437263)
Gepubliceerd in: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
door: Arun Kanakkanthara (14937731)
Gepubliceerd in: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
door: Arun Kanakkanthara (14937731)
Gepubliceerd in: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
door: Stéphane Fattori (15048281)
Gepubliceerd in: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
door: Laura Privitera (16015972)
Gepubliceerd in: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
door: Alexander N. Shoushtari (15023909)
Gepubliceerd in: (2025)

Supplementary Figure S1 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
door: Anita L. Ray (15313398)
Gepubliceerd in: (2025)

Supplementary Figure S2 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
door: Anita L. Ray (15313398)
Gepubliceerd in: (2025)

Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
door: Simon P. Beyaert (17141915)
Gepubliceerd in: (2025)

Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
door: Simon P. Beyaert (17141915)
Gepubliceerd in: (2025)

Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
door: Robin M. Hallett (15037427)
Gepubliceerd in: (2025)

Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
door: Robin M. Hallett (15037427)
Gepubliceerd in: (2025)

Supplementary Figure 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
door: Patrizia Mondello (15045002)
Gepubliceerd in: (2025)

Supplementary Figure 2 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
door: Patrizia Mondello (15045002)
Gepubliceerd in: (2025)

Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
door: Patrizia Mondello (15045002)
Gepubliceerd in: (2025)

Supplementary Figure 4 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
door: Patrizia Mondello (15045002)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_u83fg12r3do2gh1tgfbinsq77b